For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 1-10 results of 13
Gynecologic Cancer

GOG-0263

Official Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Study Purpose: To determine if adding chemotherapy to radiation therapy (CRT) can prevent or lengthen the time to recurrence when compared to radiation therapy (RT) alone.
Status: Recruiting
Gynecologic Cancer

GOG-3029/ENGOT-ov50/INNOVATE-3, EF-28

Official Title: Pivotal, Randomized, Open-Label Study Of Tumor Treating Fields (TTFields, 200khz) Concomitant With Weekly Paclitaxel For The Treatment Of Recurrent Ovarian Cancer
Study Purpose: To compare treatment using TTFields together with standard of care chemotherapy (called Paclitaxel) to standard of care chemotherapy (Paclitaxel) without TTFields. This study will help determine if using TTFields with chemotherapy is better than the usual approach of chemotherapy alone.
Status: Recruiting
Gynecologic Cancer

Gradalis CL-PTL-135

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research
Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.
Status: Recruiting
Gynecologic Cancer

GY023

Official Title: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Study Purpose: To compare the usual treatment alone to using combinations of durvalumab (MEDI4736), olaparib, and cediranib to increase the duration of time that your cancer does not progress.
Status: Recruiting
Gynecologic Cancer

InterVenn OVACA-001

Official Title: Clinical Validation of the InterVenn Ovarian Cancer Liquid Biopsy: VOCAL Study
Study Purpose: To evaluate the clinical performance for the InterVenn Ovarian Cancer Liquid Biopsy by collecting and storing blood samples and characterizing protein biomarkers in the blood of cancer vs. non-cancer patients.
Status: Recruiting
Gynecologic Cancer

LAE002INT2001/GOG-3044

Official Title: An Open-Label Randomized Active- Controlled Phase Ii Clinical Study To Assess The Efficacy And Safety Of Afuresertib Plus Paclitaxel Versus Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer
Study Purpose: To evaluate the efficacy of afuresertib in combination with paclitaxel when compared to paclitaxel alone in patients with platinum-resistant ovarian cancer.
Status: Pending
Gynecologic Cancer

NRG CC008

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.
Status: Recruiting
Gynecologic Cancer

NRG GY009

Official Title: A Randomized, Phase II/III Study Of Pegylated Liposomal Doxorubicin And Ctep-Supplied Atezolizumab (Ind #134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab And Ctep-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab In Platinum Resistant Ovarian Cancer
Study Purpose: To compare any good and bad effects of adding Atezolizumab to the usual chemotherapy, (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab.
Status: Recruiting
Gynecologic Cancer

NRG GY014

Official Title: A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma
Study Purpose: To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer. 
Status: Suspended
Gynecologic Cancer

NRG GY018

Official Title: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Endometrial Cancer.
Study Purpose: The purpose of this study is to compare any good and bad effects of adding immunotherapy drugs to the usual combination of chemotherapy drugs.
Status: Recruiting